bioRxivMolecular BiologyPreprint
A genome-wide CRISPR/Cas phenotypic screen formodulators of DUX4 cytotoxicity reveals screen complications
Ator Ashoti, Francesco LimoneiD, Melissa van Kranenburg, Anna AlemanyiD, Mirna Lilian Baak, Judith Vivié, Federica PiccioniiD, Menno P. CreyghtoniD, Kevin C. EgganiD, Niels GeijseniD
Abstract
Facioscapulohumeral muscular dystrophy (FHSD), a fundamentally complex muscle disorder that thus far remains untreatable. As the name implies, FSHD starts in the muscles of the face and shoulder gridle. The main perturbator of the disease is the pioneer transcription factor DUX4, which is misexpressed in affected tissues due to a failure in epigenetic repressive mechanisms. In pursuit of unraveling the underlying mechanism of FSHD and finding potential therapeutic targets or treatment options, we performed an exhaustive genome-wide CRISPR/Cas9 phenotypic rescue screen to identify modulators of DUX4 cytotoxicity. We found no key effectors other than DUX4 itself, suggesting treatment efforts in FSHD should be directed towards its direct modulation. The screen did however reveal some rare and unexpected Cas9-induced genomic events, that may provide important considerations for planning future CRISPR/Cas9 knock-out screens.
- organism: human
- assay: CRISPR screen
- research focus: perturbation response prediction
- approach: experimental assay
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hit-and-run silencing of endogenous DUX4 by targeting DNA hypomethylation on D4Z4 repeats in facioscapulohumeral muscular dystrophy
M. Sasaki-Honda, T. Jonouchi, … H. Sakurai·bioRxiv·Apr 12, 2022
- In vitro and in silico characterization of competitive inhibition and repression of DUX4 target gene activation as a therapeutic approach for facioscapulohumeral muscular dystrophy (FSHD)
Heloise M. Hoffmann, Alice Finkelstein, … Phillip Kyriakakis·bioRxiv·Aug 20, 2026
- Sustained efficacy of CRISPR-Cas13b gene therapy for FSHD is challenged by immune response to Cas13b
Afrooz Rashnonejad, Manal Farea, … Scott Q. Harper·bioRxiv·Dec 18, 2024
- Identification of compounds that repress DUX4 expression in facioscapulohumeral muscular dystrophy
Ning Chang, Hannah P. Moore, … Peter L. Jones·Scientific ReportsPeer-reviewed·Jun 16, 2026
- Developmental regulators drive DUX4 expression in facioscapulohumeral muscular dystrophy
Amelia Fox, Jonathan Oliva, … Francis M. Sverdrup·bioRxiv·May 21, 2024
- Posttranslational modifications of the DUX4 protein impact toxic function
Renatta N. Knox, Jocelyn O. Eidahl, … Scott Q. Harper·bioRxiv·Jul 22, 2022